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Abstract
Objective: Summarize data on metabolic syndrome (MS) in bipolar disorder (BD). Methods: A 
systematic review of the literature was conducted using the Medline, Embase and PsycInfo 
databases, using the keywords “metabolic syndrome”, “insulin resistance” and “metabolic X 
syndrome” and cross-referencing them with “bipolar disorder” or “mania”. The following types of 
publications were candidates for review: (i) clinical trials, (ii) studies involving patients diagnosed 
with bipolar disorder or (iii) data about metabolic syndrome. A 5-point quality scale was used to 
assess the methodological weight of the studies. Results: Thirty-nine articles were selected. None 
RIVWXGLHVUHDFKHGWKHPD[LPXPTXDOLW\VFRUHRISRLQWV7KHSUHYDOHQFHRI06ZDVVLJQLÀFDQWO\
higher in BD individuals when compared to a control group. The analysis of MS subcomponents 
VKRZHGWKDWDEGRPLQDOREHVLW\ZDVKHWHURJHQHRXV,QGLYLGXDOVZLWK%'KDGVLJQLÀFDQWO\KLJKHU
rates of hypertriglyceridemia than healthy controls. When compared to the general population, 
WKHUHZHUHQRVLJQLÀFDQWGLIIHUHQFHVLQWKHSUHYDOHQFHRIORZ+'/FLQLQGLYLGXDOVZLWK%''DWD
RQK\SHUWHQVLRQZHUHDOVR LQFRQFOXVLYH5DWHVRIK\SHUJO\FHPLDZHUHVLJQLÀFDQWO\JUHDWHU LQ
patients with BD compared to the general population. Conclusions: The overall results point to 
the presence of an association between BD and MS, as well as between their subcomponents.
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Introduction
Bipolar disorder (BD) is a chronic disease characterized 
by extreme changes in mood polarity. Onset typically 
occurs between adolescence and early adulthood. 
BD is associated with impairments in social and 
neuropsychological development, resulting in a high 
level of overall impairment. BD is the sixth leading cause 
of disability in the world and has a global prevalence 
estimated at .8%.1 
In addition to the psychiatric symptoms associated with 
BD, there is also evidence suggesting that BD patients are 
at increased risk for clinical diseases in comparison to 
healthy controls. A sedentary lifestyle, smoking, and an 
unhealthy diet are prejudicial factors, as are metabolic 
disorders and neurological/cardiovascular diseases.2 As 
a result, patients with BD have a life expectancy that is 
reduced by 25 to 30 years.3
Among the clinical diseases that are comorbid 
with BD, there is evidence of a high rate of metabolic 
syndrome (MS) in bipolar patients. MS is collection of 
metabolic risk factors with an unknown etiologic basis and 
pathophysiological mechanisms that increases the chances 
of developing cardiovascular disease and type 2 diabetes.3 
The prevalence of MS in the world population ranges from 
6.0% to 70.3%, depending on variables such as diagnosis 
criteria, comorbidities, ethnic group and sex.4
In bipolar patients, MS comorbidity is associated with 
a more complex disease, a less favorable response to 
treatment, and adverse courses and outcomes, such as 
an increased risk for depressive symptoms and episodes, 
including the risk of suicide.5,6 
Thus, the aim of this study is to summarize data on 
metabolic syndrome in patients with BD.
Methods
To identify studies that are relevant to the current 
study, a systematic review was conducted with the 
Medline, Embase and PsycInfo databases, using the 
keywords “metabolic syndrome”, “insulin resistance” 
and “metabolic X syndrome”, and cross-referencing 
them with “bipolar disorder” or “mania”. The search was 
conducted during May of 2012 and was limited to human 
studies published in English. Duplicated articles were 
excluded. The remaining paper titles and abstracts 
were used to determine whether the reference might be 
pertinent to the review. The following types of publications 
were candidates for review: (i) clinical trials, (ii) studies 
involving patients diagnosed with bipolar disorder, or (iii) 
data about metabolic syndrome. 
To assess the methodological weight of the studies, 
a 5-point quality scale was used that included the 
following items: a sample with at least 100 BD patients, 
a standardized BD diagnostic measure, use of the NCEP 
National Cholesterol Education Program (NCEP) or the 
International Diabetes Federation (IDF) criteria for MS, 
and a central aim of evaluating MS in BD patients or 
of comparing BD patients to controls or data from the 
general population. This quality score was based on a 
similar scoring method that used for two other published 
review articles relevant to the current study.7,8
Results
Search results
The literature search conducted using Medline, Embase and 
PsycInfo resulted in 457 articles. After the duplicate articles 
were excluded, 70 titles and abstracts were evaluated for 
pertinence. This process resulted in 39 references that were 
relevant to the present literature review. The search chart is 
shown in Figure 1, and the data extracted from these studies 
is available online as Supplementary Information. 
Quality of studies
None of the studies reached the maximum quality rating of 
5 points, mainly due to the lack of a structured BD diagnostic 
measure, the lack of a control group or general population 
comparison, or a sample size of less than 100 BD subjects.
Prevalence and demographic features
The prevalence of MS in BD patients was distributed according 
to different criteria, as presented in Table 1.
Patients with BD had a slightly higher rate of MS compared 
to the general population, but this difference failed to reach 
VLJQLÀFDQFH9-12+RZHYHUZKHQFRPSDUHGWRDFRQWUROJURXS
WKHSUHYDOHQFHRI06ZDVVLJQLÀFDQWO\KLJKHULQ%'SDWLHQWV12-16
%' SDWLHQWVZLWK06ZHUH VLJQLÀFDQWO\ ROGHU WKDQ %'
patients without MS.14,17-21 The risk of MS increased more than 
3 times in BD subjects over 30 years old12,19 when compared to 
a control group.15,16+RZHYHURQHVWXG\VKRZHGQRDVVRFLDWLRQ
of MS with age.97KHUHZHUHQRVLJQLÀFDQWGLIIHUHQFHVLQ06
rates according to gender.6,9,10,14-17,20-31 
Search results
(n = 457)
Retrieved for full-
text evaluation 
(n = 70)
Excluded after title and abstratct 
analysis 
(n = 387)
 
Exclusion criteria 
(n = 31)
- Theoretical articles and reviews
- Samples include BD and other
 disorders without discriminate  
 analysis
- Metabolic syndrome data not  
 presented
Selected for 
review 
(n = 39)
Figure 1 Flowchart of methods.
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$OWKRXJKVRPHSUHYLRXVVWXGLHVKDYHIRXQGVLJQLÀFDQWO\
higher obesity rates in BD patients compared to the general 
population11 or healthy controls,12 others have found a 
VLJQLÀFDQW GLIIHUHQFH RQO\ LQZRPHQ10  or no difference 
at all.33 Data on the differences in gender prevalence 
DUH VLPLODUO\ FRQÁLFWLQJ LQ WZR VWXGLHV IHPDOH SDWLHQWV 
KDGVLJQLÀFDQWO\KLJKHUSUHYDOHQFHUDWHVRIDEGRPLQDOREHVLW\
when compared to men,21,22 whereas another study showed 
no such difference.6
BD patients had significant higher rates of hypertri-
glyceridemia than controls.12,14-16,33 When compared to 
the general population, there was no significant differ-
ence.10 Male BD patients had significantly higher rates 
of hypertriglyceridemia when compared to female BD 
patients.6,22 
6RPHVWXGLHVSUHVHQWHGVLJQLÀFDQWO\KLJKHUSUHYDOHQFH
UDWHV RI ORZ +'/F LQ %' SDWLHQWV ZKHQ FRPSDUHG WR
controls,14-16,33 contrary to other reports that showed no 
VLJQLÀFDQWGLIIHUHQFH11,127KHSUHYDOHQFHRIORZ+'/FZDV
lower in BD patients compared to the general population, 
EXWWKDWZDVQRWVLJQLÀFDQWO\GLIIHUHQW10 Women had higher 
UDWHVRIORZ+'/FWKDQGLGPHQEXWWKLVZDVQRWVWDWLVWLFDOO\
VLJQLÀFDQW6,22:RPHQ GLG KDYH VLJQLÀFDQWO\ KLJKHU +'/F
ratios when compared to men.40 
Data on hypertension were also contradictory. Although 
one study showed similar prevalence rates in patients with 
BD and the general population,10DQRWKHUVKRZHGVLJQLÀFDQW
higher prevalence in patients.11 When compared to controls, 
RQHVWXG\SUHVHQWHGVLJQLÀFDQWO\KLJKHUUDWHVRIK\SHUWHQVLRQ
in patients,14 whereas others reported similar prevalence 
rates.12,15,16 Among BD patients, men had significantly 
higher rates of hypertension than women,6,22 with 
VLJQLÀFDQWO\KLJKHUV\VWROLFEORRGSUHVVXUHVDVZHOO40
Despite the selectivity of the criteria used, 
K\SHUJO\FHPLD UDWHVZHUH VLJQLÀFDQWO\ KLJKHU LQ SDWLHQWV
with BD when compared to the general population.10+RZHYHU 
when compared to controls, patients had a similar prevalence 
of hyperglycemia.12,14-16,33 Men and women had similar rates of 
hyperglycemia.6,22
Obesity was higher in patients with BD than controls12,15,16 
and the general population9,11 (except in one study that 
found similar prevalence rates in both groups10). BD patients 
were also reported to be more overweight than controls, 
ERWK VLJQLÀFDQWO\14 DQG QRQVLJQLÀFDQWO\12 and they were 
VLJQLÀFDQWO\PRUHRYHUZHLJKWWKDQWKHJHQHUDOSRSXODWLRQ11 
3DWLHQWVZLWK06KDGVLJQLÀFDQWO\KLJKHUERG\PDVV LQGH[
(BMI) values than those without MS,18 and it was found 
WKDW%0,ZDVVLJQLÀFDQWO\DVVRFLDWHGZLWK06 LQD ORJLVWLF
regression analysis.19
Discussion
'HVSLWHÀQGLQJVRPHFRQWUDGLFWRU\UHVXOWVZHUHSRUWRQD
body of evidence that shows a higher prevalence of MS and 
its subcomponents in bipolar patients. MS was associated with 
a poor course of illness and prognosis in bipolar individuals, 
suggesting that this is still an important issue in clinical and 
psychiatric practice.
Table 1 Prevalence of metabolic syndrome in bipolar 
GLVRUGHULQHDFKFULWHULRQGHÀQLWLRQ
Criterion Prevalence References
NCEP ATP III 16.7%-50.0% 10; 12; 14-17; 19; 20; 22; 23; 25; 26; 
28-32; 34; 36; 52; 53
IDF 25.7%-67.0% 12; 19; 20; 39; 51
NCEP ATP III: National Cholesterol Education Program Adult Treatment Panel
IDF: International Diabetes Federation.
Course of disorder and clinical outcomes
7ZRVWXGLHVRI%'SDWLHQWVUHSRUWHGQRVLJQLÀFDQWGLIIHUHQFHV
LQWKHDJHRIRQVHWRIWKHÀUVWHSLVRGHLQ%'SDWLHQWVZLWK
MS compared to those without MS.6,20+RZHYHU*XDQHWDO13 
IRXQGWKDW%'SDWLHQWVZLWK06KDGDVLJQLÀFDQWO\ROGHUPHDQ
DJHRIRQVHWRIWKHÀUVWHSLVRGHFRPSDUHGWR%'SDWLHQWV
without MS. Other studies showed that BD patients with MS 
KDGDVLJQLÀFDQWO\ODWHUDJHRIÀUVWWUHDWPHQWIRUGHSUHVVLRQ
and mania,6 D VLJQLÀFDQWO\ ORQJHU LOOQHVV GXUDWLRQ20 and a 
VLJQLÀFDQWO\JUHDWHUQXPEHURISV\FKLDWULFKRVSLWDOL]DWLRQV6 
compared to those without MS. 
Several studies found no association between psychotropic 
drug use or treatment strategy and elevated rates of 
MS.10,12,14,22,32-34 +RZHYHU PRUH RI WKH VXEMHFWV WDNLQJ
olanzapine, clozapine, or lithium met criteria for MS than 
those who did not take these drugs.17,35 Patients taking only 
antipsychotics had higher MS rates than patients taking 
only mood stabilizers.24
7KHUDWHVRISV\FKLDWULFFRPRUELGLW\ZHUHQRWVLJQLÀFDQWO\
different between BD patients with and without MS,6,20 but 
%'SDWLHQWVGLGKDYHVLJQLÀFDQWO\KLJKHUUDWHVRISV\FKLDWULF
comorbidities compared with healthy controls.16 Some studies 
VKRZHGQRVLJQLÀFDQWGLIIHUHQFHLQWKHOLIHWLPHKLVWRU\RI
suicide attempts between BD patients with and without 
MS,6,9,23,36 ZKHUHDV RWKHUV IRXQG WKDW WKLVZDV VLJQLÀFDQWO\
higher in BD patients with MS.36,37
With regards to clinical comorbidities, BD patients had 
higher overall comorbidity rates than healthy controls.15,16 
%' SDWLHQWVZLWK06 KDG VLJQLÀFDQWO\ LQFUHDVHG UDWHV RI
diabetes and cardiovascular disease compared to both BD 
patients without MS14,18,22 and to the general population.11 
These patients also had a significantly greater risk of 
cardiovascular mortality and coronary heart disease when 
compared to patients without MS.38 Smoking was not 
associated with the presence14,20 or risk of MS,39 except when 
compared to controls or the general population.11,16 Bipolar 
SDWLHQWVZLWK06KDGVLJQLÀFDQWO\KLJKHUUDWHVRIDOFRKROLVP
than patients without MS,14 but they had similar alcoholism 
rates as controls16DQGVLJQLÀFDQWO\ORZHUDOFRKROLVPUDWHV 
than other diagnostic criteria.35
Subcomponents of metabolic syndrome
In the analysis of MS subcomponents, the findings on 
abdominal obesity were inconclusive. 
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The variance in results could be explained by differences 
LQWKHVDPSOHRUFRXOGUHÁHFWGLIIHUHQFHVLQWKHSUHYDOHQFH
of MS in the general population due to cultural differences 
in dietary habits, levels of physical activity and genetic 
EDFNJURXQGV7KHVHIDFWRUVPD\KDYHLQÁXHQFHGWKHDQDO\VLV
of the subcomponents as well. Indeed, the heterogeneity of 
WKHFULWHULDLVDVLJQLÀFDQWFRQFHUQUHJDUGLQJ06GLDJQRVLV41 
and could have affected the prevalence rates in the reviewed 
studies. The criteria by the NCEP ATP III and the IDF are 
the most widely used to diagnose MS, but there are some 
differences between them (Table 2). Moreover, there is a 
ODUJH FOXVWHU RI FULWHULDPRGLÀFDWLRQV WKDWPDNHV FOLQLFDO
diagnosis and research analysis challenging. 
Although the use of psychotropic drugs provides a 
common-sense explanation of some of the components 
RI06 VWXGLHV WKDWGRQRWÀQGWKLVDVVRFLDWLRQ VKRZWKDW
medications are not a simple explanation. Most BD patients 
reported polypharmaceutical drug use or had used different 
types of medication during the course of their disease. 
Because antipsychotic polytherapy increases the prevalence 
of MS compared to monotherapy,42 the use of multiple 
medications could aggravate the course of MS, resulting in 
a worse outcome.35+RZHYHUWKHFRRFFXUUHQFHRI%'ZLWK
obesity and changes in glucose metabolism are observed even 
before the existence of these medications.11 A study with 
ÀUVWHSLVRGHSV\FKRWLFSDWLHQWVVKRZHGLQFUHDVLQJUDWHVRI
obesity, hyperglycemia and dyslipidemia after using atypical 
antipsychotics.436WXGLHVZLWKÀUVWHSLVRGHRUGUXJIUHH%'
patients are required to clarify the role of medication in 
this association.
Mechanisms linking MS and bipolar disorder have been 
ODUJHO\XQLGHQWLÀHG+\SRWKHVHVKDYHHPHUJHGSRVLWLQJWKDW
both negative health behaviors, such as smoking, poor diet, 
overeating, and a sedentary lifestyle,44 and biological factors 
RI06VXFKDVK\SRWKDODPLFSLWXLWDU\DGUHQRFRUWLFDO+3$
axis and sympathoadrenal hyperactivity, and abnormalities of 
the immunologic system,45VXFKDVLQFUHDVHGSURLQÁDPPDWRU\
cytokines,46 are correlated with BD.  
Negative outcomes such as psychiatric and physical 
comorbidities could also be explained by the concept 
RI DOORVWDWLF ORDG $/$/ UHVXOWV IURP DQ RYHUORDG LQ
the allostatic processes due to the chronic overactivity 
or inactivity of the physiological systems (such as the 
hypothalamic-pituitary-adrenal axis) that are involved in 
the capacity to achieve stability through adaptation to 
internal and external demands (i.e., allostasis). Patients 
ZLWKDKLJKHU$/ZHUH IRXQGWRKDYHDQ LQFUHDVHG ULVNRI
incidental cardiovascular disease and all-cause mortality, 
which is in accordance with the increased prevalence in 
found in BD patients of medical conditions such as diabetes, 
hypertension, ischemic heart disease and stroke.47 All of 
those correlated factors, such as neuroendocrinal and 
LQÁDPPDWRU\DEQRUPDOLWLHVWKHXVHRISV\FKRWURSLFGUXJV
and negative health behaviors, act like allostatic components 
WKDWUHLQIRUFHWKHUROHRI$/LQ%'06DVVRFLDWLRQ
Several limitations were noted during the review of 
the cited articles in the current study. First, differing 
experimental designs and sampling methodologies make 
formal comparison between studies difficult. Different 
criteria used to diagnose MS and the lack of a structured 
GLDJQRVWLF LQWHUYLHZ WR FRQÀUP D ELSRODU GLDJQRVLV GLG
not allow for standardization of the results. Additionally, 
most of the studies were cross-sectional. Because of this 
limitation, a causal relationship between bipolar disorder 
and metabolic syndrome could not be established. The 
medication treatment regimen may also be a liability, evoking 
the need for longitudinal studies.  
In conclusion, the association between MS and BD, 
although not clear, is important to consider, as BD patients 
have other risks factors for MS, such as increased rates of 
cardiovascular disease and diabetes. Because cardiovascular 
risk is increased in bipolar patients, and because of the 
negative impact of MS on general physical and psychological 
well-being and functioning, MS could contribute to a worse 
prognosis for BD and vice-versa. Therefore, psychiatrists 
should be aware of the risk factors involved in MS 
and should intervene as soon as possible to prevent metabolic 
Table 2 1&(3DQG,')GHÀQLWLRQVIRUPHWDEROLFV\QGURPH
Risk factors NCEP levels (2002) 1&(3,,,PRGLÀHG IDF levels (2006)
Abdominal obesity WC > 102 for men 
WC > 88 for women
WC > 102 for men 
WC > 88 for women
:&FPIRUPHQ(XURSH
:&FPIRUZRPHQ
or BMI > 30 kg/m2
Triglycerides
PJG/ PJG/PPRO/ PJG/PPRO/
RUVSHFLÀFWUHDWPHQWIRUWKLVOLSLGDEQRUPDOLW\
+'/FKROHVWHURO PJG/IRUPHQ
PJG/IRUZRPHQ
PJG/PPRO/LQPHQ
PJG/PPRO/LQZRPHQ
PJG/PPRO/LQPHQ
PJG/PPRO/LQZRPHQ
RUVSHFLÀFWUHDWPHQWIRUWKLVOLSLGDEQRUPDOLW\
Blood pressure PP+J PP+J
or current use of antihypertensive drugs
PP+J
or treatment of previously diagnosed hypertension 
Fasting glucose PJG/ PJG/PPRO/ PJG/PPRO/
or previous diagnosis of type 2 diabetes 
NCEP ATP III: National Cholesterol Education Program  Adult Treatment Panel; IDF: International Diabetes Federation; WC: waist circumference;  
BMI: body mass index.
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DEQRUPDOLWLHVWKDWFRXOGLQÁXHQFHWKHSURJQRVLVRIELSRODU
disorder. Such strategies include monitoring the patient’s 
lifestyle, eating habits and exercise routine.
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